Health
J&J’s COVID-19 vaccine 66 per cent effective in trial – The Tribune India
The vaccine is 85 per cent effective in stopping severe disease and preventing hospitalisation

January 29
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large trial against multiple variants across three continents.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.
A high bar has been set by two authorised vaccines from Pfizer/BioNTech and Moderna,…
-
General22 hours ago
Wondering about winter | The Spectator Australia
-
Noosa News21 hours ago
Jane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
General21 hours ago
Parents of Heidi, 3, remember ‘beautiful’ daughter killed in Ocean Grove crash
-
Noosa News19 hours ago
This 42-Kilometre Walking Trail on the NSW North Coast Weaves Through Ancient Rainforest, Volcanic Mountains and Spectacular Waterfalls